Page 8 - Sara Hurvitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antibody Drug Boosts Survival for Type of Advanced Breast Cancer

THURSDAY, Dec. 8, 2022 (HealthDay News) A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven t responded to other

United statesSan antonioSara hurvitzLos angelesIan kropCarlos arteagaGeffen school of medicineUniversity of californiaUt southwestern medical centerYale cancer centerDrug administrationJonsson comprehensive cancer centerSimmons comprehensive cancer centerHealthday newsSan antonio breast cancerMedical center

Ambrx (AMAM) Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

Ambrx (AMAM) Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesSara hurvitzDaniel oconnorBiologics epbsAmbrx biopharma incProfessor at david geffen school of medicineEngineered precision biologicsSpotlight poster presentationAntonio breast cancer symposiumDanielo connorChief executive officerNovocodex biopharmaceuticalsDavid geffen schoolSan antonio breast cancer symposiumSpotlight poster discussion

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioMike moyerSara hurvitzDaniel oconnorMike tattoryBiologics epbsExchange commissionLifesci communicationsAmbrx biopharma incProfessor at david geffen school of medicineWall streetSpotlight poster presentationAntonio breast cancer symposiumDrug conjugateEngineered precision biologics

UCLA in the News December 9, 2022

Highlights from ABC News, the Atlantic, NBC’s “Today” and others.

United statesSan diegoLos angeles countyLos angelesSara hurvitzAnne rimoinLindsay wileyDonald shoupRichard hasenZev yaroslavskyTimothy fongElon muskSarah robertsJerry nickelsburgNoa pinter wollmanGeffen school of medicine

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

San antonioUnited statesSara hurvitzDaiichi sankyoGenentech rocheEli lillyEmily hendersonUniversity of california los angelesGilead sciencesDavid geffen school of medicineJonsson comprehensive cancer centerPieris pharmaceuticalsRadius healthOrinoco pharmaceuticalsSan antonio breast cancer symposiumDavid geffen school